Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression.

Ets transcription factors control multiple biological processes, including cell proliferation, differentiation, apoptosis, angiogenesis, transformation, and invasion. Pdef is an Ets transcription factor originally identified in prostate tissue. We demonstrate that human Pdef is expressed at high levels primarily in tissues with high epithelial cell content, including prostate, colon, and breast. We also determined that Pdef protein is reduced in human invasive breast cancer and is absent in invasive breast cancer cell lines. We next assessed the functional consequences of these observations. Significantly, expression of Pdef in breast cancer cells leads to inhibition of invasion, migration, and growth. Expression of Pdef also results in the down-regulation of urokinase-type plasminogen activator and activation of the promoter of the tumor suppressor gene, MASPIN: Growth-suppressive effects of Pdef expression are mediated in part by a G(0)-G(1) cell cycle arrest associated with elevated p21 levels. Collectively, these results indicate that Pdef loss may alter the expression of genes controlling progression to invasive breast cancer.

[1]  D. Welch,et al.  Genetic Basis of Human Breast Cancer Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[2]  V. Sementchenko,et al.  The epithelial-specific Ets factors occupy a unique position in defining epithelial proliferation, differentiation and carcinogenesis. , 2003, Anticancer research.

[3]  M. Szyf,et al.  Regulation of DNA Methylation in Human Breast Cancer , 2002, The Journal of Biological Chemistry.

[4]  B. Clurman,et al.  p53 and p21 Form an Inducible Barrier that Protects Cells against Cyclin E-cdk2 Deregulation , 2002, Current Biology.

[5]  F. Rösel,et al.  Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer. , 2002, Biochemical and biophysical research communications.

[6]  M. Duffy.  Urokinase Plasminogen Activator and Its Inhibitor, Pai-1, as Prognostic Markers in Breast Cancer: from Pilot to Level 1 Evidence Studies , 2002 .

[7]  V. Sementchenko,et al.  Ets1 Is an Effector of the Transforming Growth Factor β (TGF-β) Signaling Pathway and an Antagonist of the Profibrotic Effects of TGF-β* , 2002, The Journal of Biological Chemistry.

[8]  Hong Duan,et al.  Role for DNA methylation in the control of cell type–specific maspin expression , 2002, Nature Genetics.

[9]  Steven F. Dowdy,et al.  Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes , 2002 .

[10]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[11]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[12]  Steven F Dowdy,et al.  Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. , 2002, Current opinion in genetics & development.

[13]  C. Paweletz,et al.  New approaches to proteomic analysis of breast cancer , 2001, Proteomics.

[14]  J. Kreidberg,et al.  Urokinase Receptors Promote β1 Integrin Function through Interactions with Integrin α3β1 , 2001 .

[15]  M. Ranson,et al.  The topology of plasminogen binding and activation on the surface of human breast cancer cells , 2001, British Journal of Cancer.

[16]  J. Marks,et al.  A SAGE (serial analysis of gene expression) view of breast tumor progression. , 2001, Cancer research.

[17]  M. Duffy,et al.  Biochemical markers in breast cancer: which ones are clinically useful? , 2001, Clinical biochemistry.

[18]  S. Ethier,et al.  Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. , 2001, Cancer research.

[19]  V. Sementchenko,et al.  Ets target genes: past, present and future , 2000, Oncogene.

[20]  R. Sager,et al.  The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. , 2000, Cancer research.

[21]  Duanduan Ma,et al.  Exit from G1 and S Phase of the Cell Cycle Is Regulated by Repressor Complexes Containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF , 2000, Cell.

[22]  T. Kuroki,et al.  Involvement of protein kinase C delta (PKCdelta) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCdelta. , 2000, The Journal of biological chemistry.

[23]  M. Hendrix,et al.  Epigenetic silencing of maspin gene expression in human breast cancers , 2000, International journal of cancer.

[24]  T. Miki,et al.  Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. , 2000, Cancer research.

[25]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[26]  T. Libermann,et al.  PDEF, a Novel Prostate Epithelium-specific Ets Transcription Factor, Interacts with the Androgen Receptor and Activates Prostate-specific Antigen Gene Expression* , 2000, The Journal of Biological Chemistry.

[27]  M. Nozaki,et al.  Cloning and expression of the mouse Pse gene encoding a novel Ets family member. , 2000, Gene.

[28]  T. Kuroki,et al.  Involvement of Protein Kinase C d ( PKC d ) in Phorbol Ester-induced Apoptosis in LNCaP Prostate Cancer Cells , 2000 .

[29]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[30]  J. Sipley,et al.  Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion* , 1999, The Journal of Biological Chemistry.

[31]  S. Rabbani,et al.  Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: Role of DNA methylation. , 1999, International journal of cancer.

[32]  B. Kacinski,et al.  Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. , 1998, Cancer research.

[33]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Sager,et al.  Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Wen-Lin Kuo,et al.  ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis , 1997, Oncogene.

[36]  R. Sager,et al.  Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[37]  B. Vandenbunder,et al.  PEA3 transactivates vimentin promoter in mammary epithelial and tumor cells. , 1996, Oncogene.

[38]  M. Hendrix,et al.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. , 1994, Science.

[39]  J. Marks,et al.  p53 alterations in all stages of breast cancer , 1991, Journal of surgical oncology.

[40]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[41]  R. Lidereau,et al.  Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. , 1986, Proceedings of the National Academy of Sciences of the United States of America.